DFDA

Combination Therapies (e.g., Liposomal Amphotericin B + Miltefosine)

Treatment for Visceral Leishmaniasis

Typical Dosage: Variable, e.g., L-AmB total 10-15 mg/kg + Miltefosine 7-14 days

Effectiveness
98%
Safety Score
55%
Clinical Trials
25
Participants
2.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Variable, e.g., L-AmB total 10-15 mg/kg + Miltefosine 7-14 days
Time to Effect
Days to 1 week
Treatment Duration
7-14 days
Evidence Quality
HIGH
Number Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$8,000
Side Effect Mgmt:$1,000
Total Annual:$14,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$14,286
Cost per Remission
$14,286
Comparison vs Liposomal Amphotericin B (monotherapy)
Cost Difference
$-500/year
Less expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Combination Therapies (e.g., Liposomal Amphotericin B + Miltefosine) Outcomes

for Visceral Leishmaniasis

Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Remission Rate
+98%
Common Side Effects
Infusion-related reactions (fever, chills)
+15%
Nausea/Vomiting/Diarrhea
+15%
Nephrotoxicity (creatinine elevation)
+8%
Hypokalemia
+5%

Sources:

ajtmh.org
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov